Clinical, radiological, and biomarker outcomes following a switch from MabThera® to the rituximab biosimilar Rixathon® in multiple sclerosis.

Haghgoy A, Fällmar D, Tolf A, Burman J

Mult Scler Relat Disord 117 (-) 108054 [2026-11-10; online 2026-11-10]

Rituximab is widely used off-label for multiple sclerosis (MS) in Sweden, and many centres have transitioned from originator rituximab (MabThera®) to biosimilars for economic reasons. Evidence on outcomes following a switch to the biosimilar Rixathon® in MS remains limited. Effectiveness and safety of rituximab before and after a switch from MabThera® to Rixathon® in routine health care. This retrospective observational cohort study was conducted at Uppsala University Hospital, Sweden, using prospectively collected data from the Swedish MS Registry and medical records. Patients receiving MabThera® who switched to Rixathon® from January 1, 2023 were included if they had follow-up and at least one plasma neurofilament light chain (pNfL) and/or MRI assessment in each treatment period. The primary outcome was pNfL; secondary outcomes included MRI activity, relapses, Expanded Disability Status Scale (EDSS) trajectories, no evidence of disease activity (NEDA), and serious adverse events (CTCAE grade 3-5). Longitudinal outcomes were analysed using mixed-effects models with time centred at the switch. The study was registered at ClinicalTrials.gov (NCT07235644). The cohort comprised 136 patients (median age 45 years; 70% women), contributing 1012 pNfL measurements. pNfL decreased during MabThera® treatment and remained stable at low levels after switching to Rixathon®, consistent with a transition from treatment initiation to maintenance. Age-adjusted pathological pNfL values occurred in 34/135 (25%) patients during MabThera® and 16/132 (12%) during Rixathon® (p = 0.001). Among 773 brain MRI examinations (n = 129), no new or enlarging T2 lesions or gadolinium-enhancing lesions were detected after the switch. Relapse rates were low in both periods, EDSS slopes did not differ significantly, and serious adverse events were uncommon. In this real-world MS cohort, switching from MabThera® to the biosimilar Rixathon® provided evidence of maintained disease control, with no new safety signal observed during follow-up.

Bioinformatics (NBIS) [Service]

Bioinformatics Support and Infrastructure [Service]

Bioinformatics Support, Infrastructure and Training [Service]

PubMed 43033548

DOI 10.1016/j.msard.2026.108054

Crossref 10.1016/j.msard.2026.108054

pii: S2211-0348(26)01089-8


Publications 9.5.2